Δευτέρα 13 Φεβρουαρίου 2023

Concerns on Bebtelovimab (LY‐CoV1404) used to neutralize Omicron subvariants

AlexandrosSfakianakis shared this article with you from Inoreader

Abstract

Bebtelovimab (LY-CoV1404) is a monoclonal antibody showing remarkable neutralizing capacity against all SARS-CoV-2 variants of concern (VOCs) as of June 2022, including the Omicron variant and its subvariants

This article is protected by copyright. All rights reserved.

View on Web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου